Biomea Fusion Inc (BMEA)
10.52
+0.06
(+0.57%)
USD |
NASDAQ |
May 31, 16:00
10.52
0.00 (0.00%)
Pre-Market: 20:00
Biomea Fusion Cash from Operations (Quarterly): -32.03M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -32.03M |
| December 31, 2023 | -22.84M |
| September 30, 2023 | -23.90M |
| June 30, 2023 | -25.81M |
| March 31, 2023 | -24.04M |
| December 31, 2022 | -20.20M |
| September 30, 2022 | -16.80M |
| June 30, 2022 | -15.43M |
| March 31, 2022 | -9.994M |
| Date | Value |
|---|---|
| December 31, 2021 | -15.90M |
| September 30, 2021 | -8.988M |
| June 30, 2021 | -6.476M |
| March 31, 2021 | -4.075M |
| December 31, 2020 | -2.736M |
| September 30, 2020 | -1.102M |
| June 30, 2020 | -0.369M |
| March 31, 2020 | -0.252M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-32.03M
Minimum
Mar 2024
-0.252M
Maximum
Mar 2020
-13.58M
Average
-15.43M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
| Poseida Therapeutics Inc | -15.14M |
| Cartesian Therapeutics Inc | -15.92M |
| BioXcel Therapeutics Inc | -17.71M |
| NovaBay Pharmaceuticals Inc | -1.572M |
| Palatin Technologies Inc | -8.607M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.035M |
| Cash from Financing (Quarterly) | 0.116M |
| Free Cash Flow | -105.08M |
| Free Cash Flow Per Share (Quarterly) | -0.8934 |
| Free Cash Flow Yield | -28.00% |